Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals for a fifth and final year, through October 2010. The alliance, initiated in 2005, is focused on the discovery, development, and commercialization of RNAi therapeutics toward Novartis-selected disease gene targets. Both companies are responsible for RNAi discovery activities and Novartis is responsible for development and commercialization of RNAi therapeutic products. Novartis will continue to fund R&D...